Last reviewed · How we verify

Decabid — Competitive Intelligence Brief

Decabid (INDECAINIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Sodium channel protein type 5 subunit alpha Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Decabid (INDECAINIDE) — Eli Lilly.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Decabid TARGET INDECAINIDE Eli Lilly marketed Sodium channel protein type 5 subunit alpha 1989-01-01
Ranexa RANOLAZINE Menarini Intl marketed Anti-anginal [EPC] Sodium channel protein type 5 subunit alpha 2006-01-01
Cerebyx FOSPHENYTOIN Pfizer marketed Anti-epileptic Agent Sodium channel protein type 5 subunit alpha 1996-01-01
Naropin ROPIVACAINE Fresenius Kabi marketed Amide Local Anesthetic Sodium channel protein type 5 subunit alpha 1996-01-01
ENCAINIDE ENCAINIDE marketed encainide Sodium channel protein type 5 subunit alpha 1986-01-01
Tessalon benzonatate Generic (originally Pfizer) marketed Non-narcotic Antitussive [EPC] Sodium channel protein type 5 subunit alpha 1958-01-01
PIRMENOL PIRMENOL marketed pirmenol Sodium channel protein type 5 subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Decabid — Competitive Intelligence Brief. https://druglandscape.com/ci/indecainide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: